RM LAW, P.C. is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell the Company to ImmunityBio, Inc.
If you own shares of NantKwest and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here. You may also email Mr. Maniskas at firstname.lastname@example.org.
On December 21, 2020, NantKwest announced that it had entered into an agreement to merge with ImmunityBio, a privately-held company, in a stock-for-stock transaction. Following the closing of the transaction, NantKwest shareholders will only own approximately 28% of the combined company. Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. Upon completion of the merger, NantKwest shareholder will only own approximately 28% of the combined company.